Medexus Pharmaceuticals Inc. (MDP.TO)
CAD 2.04
(-5.99%)
CAD 2.04
(-5.99%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 125.41 Million USD | -9.7% |
| 2022 | 138.88 Million USD | 14.37% |
| 2021 | 121.43 Million USD | -6.94% |
| 2020 | 130.49 Million USD | 32.44% |
| 2019 | 98.53 Million CAD | 72.45% |
| 2018 | 57.13 Million CAD | 1086.34% |
| 2017 | 4.81 Million CAD | -0.14% |
| 2016 | 4.82 Million CAD | 29.18% |
| 2015 | 3.73 Million CAD | 3.3% |
| 2014 | 3.61 Million CAD | 162.62% |
| 2013 | 1.37 Million CAD | 7794.83% |
| 2012 | 17.43 Thousand CAD | -62.52% |
| 2011 | 46.51 Thousand CAD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 114.67 Million USD | -8.56% |
| 2023 Q4 | 125.41 Million USD | -4.13% |
| 2023 Q1 | 144.14 Million USD | 3.79% |
| 2023 Q2 | 144.43 Million USD | 0.2% |
| 2023 Q3 | 130.81 Million USD | -9.43% |
| 2023 FY | 125.41 Million USD | -9.7% |
| 2022 Q1 | 118.83 Million USD | -2.14% |
| 2022 Q4 | 138.88 Million USD | 6.1% |
| 2022 Q3 | 130.89 Million USD | 4.41% |
| 2022 FY | 138.88 Million USD | 14.37% |
| 2022 Q2 | 125.36 Million USD | 5.49% |
| 2021 Q2 | 113.22 Million USD | -13.9% |
| 2021 Q4 | 121.43 Million USD | 5.6% |
| 2021 Q3 | 114.98 Million USD | 1.56% |
| 2021 Q1 | 131.49 Million USD | 0.77% |
| 2021 FY | 121.43 Million USD | -6.94% |
| 2020 Q2 | 102.99 Million CAD | -1.9% |
| 2020 FY | 130.49 Million USD | 32.44% |
| 2020 Q3 | 133.74 Million CAD | 29.85% |
| 2020 Q4 | 130.49 Million USD | -2.43% |
| 2020 Q1 | 104.98 Million CAD | 6.55% |
| 2019 Q4 | 98.53 Million CAD | 58.27% |
| 2019 FY | 98.53 Million CAD | 72.45% |
| 2019 Q3 | 62.25 Million CAD | 5.24% |
| 2019 Q1 | 61.39 Million CAD | 7.45% |
| 2019 Q2 | 59.15 Million CAD | -3.64% |
| 2018 Q1 | 5.06 Million CAD | 5.21% |
| 2018 Q4 | 57.13 Million CAD | 40.7% |
| 2018 FY | 57.13 Million CAD | 1086.34% |
| 2018 Q2 | 7.93 Million CAD | 56.65% |
| 2018 Q3 | 40.6 Million CAD | 411.58% |
| 2017 FY | 4.81 Million CAD | -0.14% |
| 2017 Q1 | 4.98 Million CAD | 3.28% |
| 2017 Q4 | 4.81 Million CAD | 4.01% |
| 2017 Q3 | 4.63 Million CAD | -5.73% |
| 2017 Q2 | 4.91 Million CAD | -1.39% |
| 2016 Q3 | 4.24 Million CAD | 7.86% |
| 2016 FY | 4.82 Million CAD | 29.18% |
| 2016 Q2 | 3.93 Million CAD | -2.23% |
| 2016 Q4 | 4.82 Million CAD | 13.66% |
| 2016 Q1 | 4.02 Million CAD | 7.77% |
| 2015 Q2 | 3.48 Million CAD | -7.43% |
| 2015 Q1 | 3.75 Million CAD | 4.02% |
| 2015 FY | 3.73 Million CAD | 3.3% |
| 2015 Q4 | 3.73 Million CAD | 3.77% |
| 2015 Q3 | 3.59 Million CAD | 3.38% |
| 2014 Q3 | 436.49 Thousand CAD | -17.85% |
| 2014 Q2 | 531.36 Thousand CAD | 7.83% |
| 2014 FY | 3.61 Million CAD | 162.62% |
| 2014 Q1 | 492.77 Thousand CAD | 0.0% |
| 2014 Q4 | 3.61 Million CAD | 728.02% |
| 2013 Q1 | 498.97 CAD | 0.0% |
| 2013 Q2 | 2280.97 CAD | 357.13% |
| 2013 Q3 | 1.84 Million CAD | 80617.78% |
| 2013 FY | 1.37 Million CAD | 7794.83% |
| 2012 Q1 | - CAD | -100.0% |
| 2012 Q2 | - CAD | 0.0% |
| 2012 FY | 17.43 Thousand CAD | -62.52% |
| 2012 Q4 | - CAD | -100.0% |
| 2012 Q3 | 17.43 Thousand CAD | 0.0% |
| 2011 FY | 46.51 Thousand CAD | 0.0% |
| 2011 Q3 | 46.51 Thousand CAD | 0.0% |
| 2011 Q4 | 15.84 Thousand CAD | -65.94% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Aurora Cannabis Inc. | 236.8 Million CAD | 47.04% |
| Avicanna Inc. | 13.99 Million CAD | -795.85% |
| Avant Brands Inc. | 33.22 Million CAD | -277.468% |
| Cardiol Therapeutics Inc. | 8.45 Million CAD | -1383.44% |
| Crescita Therapeutics Inc. | 5.77 Million CAD | -2071.226% |
| Knight Therapeutics Inc. | 198.62 Million CAD | 36.86% |
| MediPharm Labs Corp. | 10.93 Million CAD | -1047.183% |
| OrganiGram Holdings Inc. | 26.83 Million CAD | -367.39% |
| Canopy Growth Corporation | 799.82 Million CAD | 84.32% |
| Willow Biosciences Inc. | 3.23 Million CAD | -3774.266% |
| Auxly Cannabis Group Inc. | 210.85 Million CAD | 40.524% |